Show simple item record

dc.contributor.authorGridelli, C
dc.contributor.authorde Marinis, F
dc.contributor.authorThomas, M
dc.contributor.authorPrabhash, K
dc.contributor.authorEl Kouri, C
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorBustin, F
dc.contributor.authorPujol, J
dc.contributor.authorJohn, W
dc.contributor.authorSan Antonio, B
dc.contributor.authorZimmermann, A
dc.contributor.authorChouaki, N
dc.contributor.authorVisseren-Grul, C
dc.contributor.authorPaz-Ares, L
dc.date.accessioned2014-08-05T13:59:16Z
dc.date.available2014-08-05T13:59:16Z
dc.date.issued2014-07
dc.identifier.citationFinal efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study. 2014, 9 (7):991-7 J Thorac Oncolen
dc.identifier.issn1556-1380
dc.identifier.pmid24926544
dc.identifier.doi10.1097/JTO.0000000000000207
dc.identifier.urihttp://hdl.handle.net/10541/324254
dc.description.abstractThe PARAMOUNT Phase III trial showed that maintenance pemetrexed after pemetrexed plus cisplatin induction was well tolerated and effective for patients with advanced nonsquamous non-small-cell lung cancer. Approximately 17% of patients receiving maintenance therapy in this study were 70 years of age or older. Here we report efficacy and safety results from the PARAMOUNT study for elderly (≥70 years) and non-elderly (<70 years) patients.
dc.language.isoenen
dc.rightsArchived with thanks to Journal of thoracic oncology : official publication of the International Association for the Study of Lung Canceren
dc.titleFinal efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study.en
dc.typeArticleen
dc.contributor.departmentDivision of Medical Oncology, S. Giuseppe Moscati Hospital, Avellino, Italyen
dc.identifier.journalJournal of Thoracic Oncologyen
html.description.abstractThe PARAMOUNT Phase III trial showed that maintenance pemetrexed after pemetrexed plus cisplatin induction was well tolerated and effective for patients with advanced nonsquamous non-small-cell lung cancer. Approximately 17% of patients receiving maintenance therapy in this study were 70 years of age or older. Here we report efficacy and safety results from the PARAMOUNT study for elderly (≥70 years) and non-elderly (<70 years) patients.


This item appears in the following Collection(s)

Show simple item record